BioSpace News Archive

Compass Therapeutics, Inc. announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009.

Neurocrine Biosciences, Inc. will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time on Tuesday, May 10, 2022 in Las Vegas.

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced financial results and operational highlights for the first quarter ended March 31, 2022.

PTC Therapeutics, Inc. announced a corporate update and financial results for the first quarter ending March 31, 2022.

Penumbra, Inc., a global healthcare company focused on innovative therapies, reported financial results for the first quarter ended March 31, 2022.

Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced its first quarter 2022 financial results and provided a corporate update.

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the first patient has been enrolled in the company’s Phase 2 RAISE Spasticity Trial.

Cerner Corporation (Nasdaq: CERN) today announced results for the 2022 first quarter that ended March 31, 2022.

Vivalink, a leading provider of digital healthcare solutions, announces availability of the world’s first multi-vital blood pressure patch for remote patient monitoring for use in commercial research and development.

Demonstrating its commitment to Advancing the Science of Human Milk®, Prolacta Bioscience® announced today that Cell Host & Microbe has published a proof-of-concept study evaluating the unique relationship between human milk oligosaccharides (HMOs) and the infant gut microbe Bifidobacterium longum subspecies infantis (B. infantis) to control B. infantis engraftment into the adult gut microbiome.